Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-08T17:37:50.415Z Has data issue: false hasContentIssue false

State of the art in assisted reproductive technologies for patients with advanced maternal age

Published online by Cambridge University Press:  22 February 2023

Taisiia Yurchuk*
Affiliation:
Institute for Problems of Cryobiology and Cryomedicine (IPC&C) of the National Academy of Sciences of Ukraine and United Nations Educational, Scientific and Cultural Organization (UNESCO) Chair in Cryobiology, Kharkiv, Ukraine
Marina Petrushko
Affiliation:
Institute for Problems of Cryobiology and Cryomedicine (IPC&C) of the National Academy of Sciences of Ukraine and United Nations Educational, Scientific and Cultural Organization (UNESCO) Chair in Cryobiology, Kharkiv, Ukraine ART-Clinic of Reproductive Medicine’, Kharkiv, Ukraine
Barry Fuller
Affiliation:
University College London Division of Surgery and Interventional Science, Royal Free London National Health Service Trust, Royal Free Campus, London, UK
*
Author for correspondence: Taisiia Yurchuk. Taisiia Yurchuk, 23 Pereyaslavska St., Kharkiv, Ukraine 61016. E-mail: [email protected]
Rights & Permissions [Opens in a new window]

Summary

According to the World Health Organization, the female reproductive age lasts up to 49 years, but problems with the realization of women’s reproductive rights may arise much earlier. Significant numbers of factors affect the state of reproductive health: socioeconomic, ecological, lifestyle features, the level of medical literacy, and the state of the organization and medical care quality. Among the reasons for fertility decline in advanced reproductive age are the loss of cellular receptors for gonadotropins, an increase in the threshold of sensitivity of the hypothalamic-pituitary system to the action of hormones and their metabolites, and many others. Furthermore, negative changes accumulate in the oocyte genome, reducing the possibility of fertilization, normal development and implantation of the embryo and healthy offspring birth. Another theory of ageing causing changes in oocytes is the mitochondrial free radical theory of ageing. Taking into account all these age-related changes in gametogenesis, this review considers modern technologies aimed at the preservation and realization of female fertility. Among the existing approaches, two main ones can be distinguished: methods allowing the preservation of reproductive cells at a younger age using ART intervention and cryobanking, as well as methods aimed at improving the basic functional state of advanced-age women’s oocytes and embryos.

Type
Review Article
Copyright
© Institute for Problems of Cryobiology and Cryomedicine National Academy of Sciences of Ukraine, 2023. Published by Cambridge University Press

Introduction

According to the World Health Organization (WHO), reproductive health is a state of complete physical, mental, and social well-being and not merely the absence of disease or infirmity in all matters related to the reproductive system and to its functions and processes (World Health Organization, 2021). Reproductive health implies that people are able to have a satisfying and safe sex life and that they have the capability to reproduce and the freedom to decide if, when, and how often to do so. Despite the fact that, according to the WHO, the reproductive age in women lasts up to 49 years (World Health Organization, 2006), problems with the realization of reproductive rights in women may arise much earlier. After 35 years, most women experience a decline in sexual functions and deteriorating general health. Of course, this does not happen to everyone, but there is a high probability that a woman will face certain difficulties at this age. A slight decrease in reproductive function is noted from 27–28 years old, becoming even more pronounced at ages between 35 and 40 years old and, by the age of 45, the reproductive function approaches zero.

Recently, women have increasingly realized their reproductive function at a later reproductive age, when they have moved forwards in their career progression and acquired a certain material status necessary for full-fledged child care and upbringing. There are constant discussions about the expediency of motherhood in advanced reproductive age.

Significant numbers of factors affect the reproductive health state: socioeconomic, ecological, lifestyle, the level of medical literacy, the state of the organization, and the quality of the available medical care (Wu et al., Reference Wu, Zhang and Wang2000). These affect a woman’s fertility in a different manner, whilst age-related changes occur in everyone.

Age-related reasons for fertility declines in women

Negative changes accumulate in the oocyte’s genome with age. This reduces the fertilization possibility, normal embryo development should fertilization have been achieved, and implantation and healthy offspring birthrates (Franasiak et al., Reference Franasiak, Forman, Hong, Werner, Upham, Treff and Scott2014). However, within the cohort of developing embryos from this group of women, many blastocysts with a euploid chromosome set number are also unable to implant and develop into living embryos. Therefore age-related ooplasm abnormalities may also reduce oocyte competence, even after fertilization and progress to adversely affect embryonic development (Capalbo et al., Reference Capalbo, Rienzi, Cimadomo, Maggiulli, Elliott, Wright, Nagy and Ubaldi2014).

Age determines the deterioration of morphological and functional oocyte characteristics, and the embryos obtained from them has a multifactorial nature. It has been shown that the diameter of the cytoplasm and the thickness of the zona pellucida decrease linearly with the age of women (Valeri et al., Reference Valeri, Pappalardo, De Felici and Manna2011). Cell volume decrease may be due to changes in ion pump activity or the ability to regulate homeostatic water balance. The decrease in oocyte quality may be associated with impaired lipid metabolism and decreased melatonin in the follicular fluid (Cordeiro et al., Reference Cordeiro, Montani, Pilau, Gozzo, Fraietta and Turco2018; Zhang et al., Reference Zhang, Lu, Chen, Zhang and Xiong2020).

Despite the contribution of the paternal genome to the embryo chromosomal balance, it is considered that the mother’s age is the main cause of embryo aneuploidies. Age-related chromosomal abnormalities mainly arise because of meiotic impairments during oogenesis, following flawed chromosome segregation patterns such as non-disjunction, premature separation of the sister chromosome, or their reverse segregation (Cimadomo et al., Reference Cimadomo, Fabozzi, Vaiarelli, Ubaldi, Ubaldi and Rienzi2018). The chromosomal aberration rate in MII stage oocytes of advanced reproductive age patients varies from 4% to 62% (Kuliev et al., Reference Kuliev, Cieslak and Verlinsky2005). A cytogenetic analysis of unfertilized oocytes showed an increase in chromosomal abnormality rate with age (Petrushko, Reference Petrushko2003). It is believed that the risks of aneuploidy may be associated with a long delay in oocyte meiosis stage I, which occurs before ovulation (Pellestor et al., Reference Pellestor, Andréo, Arnal, Humeau and Demaille2003). It is known that oocyte telomeres begin to shorten over a lifetime due to the chronic effects of oxidative and genotoxic stress, the late exit of female gametes from the cell-cycle cessation, as well as reduced telomerase activity (Keefe et al., Reference Keefe, Marquard and Liu2006), cohesin dysfunction, and meiotic spindle abnormalities (Keefe et al., Reference Keefe, Kumar and Kalmbach2015).

An evaluation of OCT4, SOX2, CDX2, GATA3, and YAP gene expression and the corresponding embryo proteins from young and advanced-age women showed that the expression of SOX2 and CDX2 genes in embryos at the morula stage in the group of women over 38 years old was statistically lower than in the group of younger patients (Gharanfoli et al., Reference Gharanfoli, Shahverdi, Dalman, Ghaznavi, Alipour and Eftekhari-Yazdi2020).

The most common specific abnormalities in embryos of women older than 36 years are sex chromosome monosomy (45,X), which accounts for almost 10% of all miscarriages, and trisomies 16, 21 and 22, which together account for 50% of all miscarriages detected in spontaneous abortions (Gharanfoli et al., Reference Gharanfoli, Shahverdi, Dalman, Ghaznavi, Alipour and Eftekhari-Yazdi2020).

Another theory of ageing causing changes in the cell, including oocytes, is the mitochondrial free radical theory of ageing (Barja, Reference Barja2014). According to this theory, reactive oxygen species (ROS) and various toxic byproducts of aerobic metabolism are probably involved in cellular damage to genomes and mitochondrial DNA (mtDNA) and are associated with mutations. The increased production of ROS caused a clear disruption in the respiratory chain of the cell, leading to the accumulation of mutations and unbalanced redox activity (Taylor and Turnbull, Reference Taylor and Turnbull2005; Fragouli et al., Reference Fragouli, Spath, Alfarawati, Kaper, Craig, Michel, Kokocinski, Cohen, Munne and Wells2015). Basal ROS levels often decline during the normal mitochondrial function phase within the respiratory chain, whilst an excess level of cellular ROS is determined by age and contributes to significantly increased oxidative damage and loss of cellular activity. Therefore, there was a change in mitochondrial function: a decrease in mitochondrial membrane potential (MMP), oxidative phosphorylation (OXPHOS), and the number of mtDNA copies in advanced-age women compared with younger women (May-Panloup et al., Reference May-Panloup, Boucret, Chao de la Barca, Desquiret-Dumas, Ferré-L’Hotellier, Morinière, Descamps, Procaccio and Reynier2016). This coincided with lower mtDNA levels for advanced-age women in embryos at the early cleavage stage, but paradoxically the opposite was observed at the blastocyst stage, with higher mtDNA levels associated with increased aneuploidy and failed implantation (Fragouli and Wells, Reference Fragouli and Wells2015; Liu et al., Reference Liu, Han, Li, Wang, Ma, Zhang, Guo, Wang, Wang, Duan, Xu, Yin and Yao2017).

ART features for advanced reproductive age women

Increases in serum progesterone and estradiol levels were observed in advanced reproductive age patients (Chahal and Drake, Reference Chahal and Drake2007). These patients have a poor response to stimulation for superovulation (Seifer et al., Reference Seifer, Baker and Leader2011). The oocyte fertilization rate was significantly lower in patients aged more than 36 years compared with younger women (Asada et al., Reference Asada, Tokoro, Sonohara, Fukunaga, Hattori and Hashiba2019). All of these factors led to the fact that the effectiveness of ART programmes in women over 40 years old was ∼5% (Zhang et al., Reference Zhang, Choo and Yang2015). These unsuccessful ART outcomes have pushed reproductive specialists and scientists to carry out scientific research to improve reproductive indicators for advanced-age women. Among the existing approaches, two main ones can be distinguished: (1) methods allowing the preservation of reproductive cells at a younger age using ART intervention and cryobanking; and (2) methods aimed at improving the existing functional indicators of oocytes and embryos of advanced-age women to aid optimal selection during ART.

Cryotechnology as the basis for preserving the reproductive potential of advanced-age women

Economically developed countries have passed laws on reproductive health protection. Scientists are developing methods to preserve reproductive health and prolong it for the longest possible period. Modern methods of preserving reproductive health and prolonging the reproductive period of women are based on cryotechnology.

Oocyte freezing for so-called ‘social reasons’ in female groups applies to women who seek to prolong, protect, and secure their fertility for later years (Simopoulou et al., Reference Simopoulou, Sfakianoudis, Bakas, Giannelou, Papapetrou, Kalampokas, Rapani, Chatzaki, Lambropoulou, Lourida, Deligeoroglou, Pantos and Koutsilieris2018). In 2013, the American Society for Reproductive Medicine, for the first time, approved the cryopreservation of oocytes as non-experimental (American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology, 2013). Experience has shown that the cryopreservation of oocytes is a promising area for maintaining female fertility. However, it is important not only to obtain a high survival rate of oocytes after cryopreservation and preserve their main function but also to ensure the absence of the negative effects of cryopreservation factors on the genome of embryos that will develop from oocytes after long-term, low-temperature storage.

Data on the chromosomal status of embryos derived from cryopreserved oocytes are quite contradictory. Some studies have found that cryopreservation factors can induce meiotic spindle abnormalities and chromosome disorganization in human oocytes, which, in turn, may increase the appearance of embryos with aneuploid chromosome set numbers (Bromfield et al., Reference Bromfield, Coticchio, Hutt, Sciajno, Borini and Albertini2009). However, we have previously shown that the level of chromosomal aneuploidy of embryos derived from cryopreserved and fresh oocytes did not exhibit significant differences (Buderatska et al., Reference Buderatska, Gontar, Ilyin, Lavrinenko, Petrushko and Yurchuk2020). It should be noted that these results were obtained in a study of women with a mean age of 27.6 ± 4.8 years.

There are very few data in the scientific literature on autologous oocyte cryopreservation for advanced-age women with successful pregnancy and childbirth (Parmegiani et al., Reference Parmegiani, Cognigni, Bernardi, Ciampaglia, Pocognoli and Filicori2009).

Recent publications have reported that the survival rate after cryopreservation has increased in recent years, which confirmed the influence of methodological approaches to female gamete cryopreservation provided using optimal ART (Pai et al., Reference Pai, Baid, Palshetkar, Pai, Pai and Palshetkar2021). The turning point in the improvement of oocyte cryopreservation methods was the use of vitrification (Kuleshova et al., Reference Kuleshova, Gianaroli, Magli, Ferraretti and Trounson1999). The absence of ice crystal formation when the temperature was lowered to −196°С and at the stage of warming made it possible to reduce the level of cell damage and significantly increase the efficiency of oocyte cryopreservation compared with slow freezing (Levi-Setti et al., Reference Levi-Setti, Patrizio and Scaravelli2016). Also, using different techniques prior to cryopreservation of oocytes and embryos at various preimplantation stages could help to preserve their functional characteristics in younger age women (Petrushko et al., Reference Petrushko, Yurchuk, Buderatska and Piniaiev2018, Reference Petrushko, Yurchuk, Piniaiev and Buderatska2019). It should be noted that the state of the endometrium is also very important when transferring embryos and contributes to the level of implantation. Women older than 38 years have reduced implantation (6.5% vs. 10.9%, P = 0.01) and pregnancy (10.1 vs. 18.7%, P = 0.02) rates compared with younger women (Borini et al., Reference Borini, Levi Setti, Anserini, De Luca, De Santis, Porcu, La Sala, Ferraretti, Bartolotti, Coticchio and Scaravelli2010). More optimistic results of the incidence of pregnancy are given in the work by Rienzi and colleagues, who found 12.6% for women in the older group compared with 27.5% for women younger than 38 years (Rienzi et al., Reference Rienzi, Cobo, Paffoni, Scarduelli, Capalbo, Vajta, Remohí, Ragni and Ubaldi2012).

The results of oocyte cryopreservation, depending on the woman’s age revealed that ‘take home baby’ rate ranged from 5% to 17% in patients older than 40 years. The birth rate in patients aged 41–42 years was 2–3% lower than in patients aged 37–40 years (Cil and Seli, Reference Cil and Seli2013).

Data from the United States Reproductive Technology Association in 2013 showed that live birth rate in cycles with fresh embryos from non-donor oocytes decreased from 21% at the age of 38–40 to 11% at the age of 41–42, with a further reduction to 4.5% for age over 42 years.

The cryopreservation of oocytes by social indicators at younger age and subsequent in vitro fertilization and embryo transfer gives women who expect to become pregnant at an advanced age two important benefits: becoming genetic parents to their own offspring and reducing the risk of having children with chromosomal abnormalities associated with aneuploidy. In addition, freezing oocytes may be the best alternative for women who do not have a partner at a particular stage in life or who have moral prejudices about embryo cryopreservation (Buderatska and Petrushko, Reference Buderatska and Petrushko2016).

The use of cryotechnology to preserve women’s fertility at a young age is not limited to the cryopreservation of oocytes. In contrast with the ‘social reasons’ for postponing conception, there are also medical ones, in which there are some contraindications for induction of superovulation to obtain mature oocytes. In these cases, ovarian tissue cryopreservation (OTC) is recommended before gonadotoxic therapy to further aid transplantation after recovery at an older age (Kim et al., Reference Kim, Lee, Lee and Kim2018a). OTC also can be offered as an alternative to preserve fertility in young patients at risk of premature ovarian insufficiency. However, despite significant advances in the development of methods for OTC, slightly more than 130 children have been born to date. Restored fertility using OTC could be realized by ovarian tissue transplantation or in vitro maturation followed by in vitro fertilization. It should be noted that transplantation of ovarian tissue has some contraindications, especially when the ovary is part of the malignancy. The efficiency of the OTC procedure is questionable at more than 36 years of age, and it is still considered experimental in many countries, where legislation and regulations vary (ESHRE Guideline Group on Female Fertility Preservation et al., Reference Anderson, Amant, Braat, D’Angelo, Chuva de Sousa Lopes, Demeestere, Dwek, Frith, Lambertini, Maslin, Moura-Ramos, Nogueira, Rodriguez-Wallberg and Vermeulen2020).

Techniques improving the oocyte and embryo quality of advanced-age women

Methods for improving fresh or cryopreserved oocyte and embryo quality are proposed. For example, methods are co-culture systems with Vero, oviduct and endometrium cells (Moshkdanian et al., Reference Moshkdanian, Nematollahi-mahani, Pouya and Nematollahi-mahani2011); microsurgical removal of fragmentation in day 2 embryos (Kim et al., Reference Kim, Kim, Park, Kwak, Yoo, Park, Sun, Kim, Lee, Park and Chi2018b); and individualization of the embryo day transfer, etc. (Yoon et al., Reference Yoon, Yoon, Son, Kim, Im and Lim2001). The most promising method of oocyte renewal takes into consideration that the mitochondrial free radical theory of ageing is mitochondrial replacement therapy (MRT). It is known that, unlike the nuclear genome that is inherited equally from both parents, the mitochondrial genome is transmitted mainly from the mother’s gamete (Zou et al., Reference Zou, Slone, Cao and Huang2020). Mitochondrial DNA is circular in structure and contains 37 genes that control the production of proteins involved in energy metabolism. Therefore an mtDNA mutation can affect organs that depend on it, giving rise to several incurable diseases such as deafness, diabetes mellitus, myopathies, glaucoma, and others (Costa et al., Reference Costa, Santana, Vilanova and Parente2016). MRT could be performed using several techniques, each of which has advantages and disadvantages.

Ooplasm transfer

The first donor cytoplasm that contained healthy mitochondria along with sperm was transferred in 1997 to a 39-year-old recipient’s oocyte cytoplasm using the ICSI procedure (Cohen et al., Reference Cohen, Scott, Schimmel, Levron and Willadsen1997). In this case, the reconstituted zygote contained the original parent’s nuclear DNA and mixed mtDNA from both donor and recipient oocytes. However, this technology was later banned due to mitochondrial heteroplasm with two types of mtDNA and chromosomal abnormalities in future offspring (Barritt et al., Reference Barritt, Brenner, Malter and Cohen2001; Mobarak et al., Reference Mobarak, Heidarpour, Tsai, Rezabakhsh, Rahbarghazi, Nouri and Mahdipour2019).

Meiotic spindle transfer

The first live birth case in humans using meiotic spindle transfer was reported by Zhang et al. (Reference Zhang, Liu, Luo, Chavez-Badiola, Liu, Yang, Munne, Konstantinidis, Wells and Huang2016a) in a 36-year-old woman diagnosed with Leigh syndrome. The metaphase II meiotic spindle was extracted from the recipient’s oocyte and transferred to a healthy donor oocyte with a pre-removed own spindle. After fertilization of the reconstructed oocyte using ICSI, the resulting zygote contained mitochondria from a healthy donor and the original nuclear DNA of the parents. Using this MRT method, less than 1% of maternally affected mtDNA was transferred to the offspring (Craven et al., Reference Craven, Tang, Gorman, De Sutter and Heindryckx2017). However, this indicator of the maternal mtDNA content may fluctuate, depending on technical aspects such as the competency of the embryologist involved.

Polar body transfer (PBT)

To perform PBT, the first polar body of the recipient’s oocyte is transferred to the enucleated donor’s oocyte. After that, the reconstructed oocyte is fertilized using the ICSI method. In addition to the first PBT, it is possible to carry out the transfer of the second PB. After fertilization, the recipient’s oocyte secretes the second polar body, which is extracted and transferred to the donor’s zygote with the previously removed female pronucleus. PBT has several advantages, such as minimum transfer of affected patient mtDNA as the PB includes few mtDNA copies and PBT yields undetectable carryover of donor mtDNA in two generations (Wang et al., Reference Wang, Sha, Ji, Zhang, Chen, Cao and Zhu2014). Also, PBT leads to less chromosomal damage due to the PB structural features and location. Moreover, for the first PBT, this technique could be used to double the number of oocytes for poor responders with the absence of mtDNA abnormalities.

Pronuclear transfer (PNT)

This technology of mitochondrial transfer is based on the fact that the pronuclei of one zygote are transferred to another enucleated zygote. To do this, a donor oocyte and an oocyte with disturbed mitochondrial DNA are fertilized with the sperm of the future father. Shortly after the appearance of the pronuclei, a pronuclear transfer is carried out into the zygote obtained from the donor oocyte. Therefore, the embryo carries the nuclear DNA from the parents, and the donor’s mitochondrial DNA.

This technique has some advantages, as pronuclei are visualized well under a light microscope without the use of additional equipment, and the fertilization procedure can be performed using ICSI as well as IVF. However, from an ethical point of view, the implementation of this technique requires the destruction of the embryo at the zygote stage, and it is this method of mitochondrial transport that has the greatest limitations in some efforts (Ishii and Hibino, Reference Ishii and Hibino2018). In addition, for the fusion of pronuclei and donor cytoplasm, the inactivated viral vector SeV (Sendai virus, also known as HVJ-E) is used (Tachibana et al., Reference Tachibana, Sparman, Sritanaudomchai, Ma, Clepper, Woodward, Li, Ramsey, Kolotushkina and Mitalipov2009; Craven et al., Reference Craven, Tuppen, Greggains, Harbottle, Murphy, Cree, Murdoch, Chinnery, Taylor, Lightowlers, Herbert and Turnbull2010). The absence of viral genetic material has been shown previously (Tachibana et al., Reference Tachibana, Sparman, Sritanaudomchai, Ma, Clepper, Woodward, Li, Ramsey, Kolotushkina and Mitalipov2009).

The first report of a successful pregnancy with a fetus bearing a normal karyotype and low heteroplasia rate was received in 2016 in a 30-year-old woman who had had two unsuccessful IVF attempts (Zhang et al., Reference Zhang, Zhuang, Zeng, Grifo, Acosta, Shu and Liu2016b), as a result of which all resulting embryos halted development at the two-cell stage.

Germinal vesicle transfer (GVT)

Immature oocytes in prophase I of the first meiosis have a nucleus that stays in the form of a ‘germinal vesicle’ until meiosis resumption. GVT is removed and transferred to a donor oocyte with a previously extruded germinal vesicle. The ooplast and karyoplast merger is conducted using electrofusion with an electro-cell manipulator then the reconstructed oocyte undergoes in vitro maturation followed by fertilization.

This technique was first applied for advanced reproductive age women by Zhang et al. (Reference Zhang, Wang, Krey, Liu, Meng, Blaszczyk, Adler and Grifo1999), however the reconstructed oocytes did not reach the mature stage.

The advantage of GVT is that it can be performed before the onset of meiosis I (MI). As mitochondria play an important role in chromosome segregation, the restoration of mitochondria prior to meiosis I may contribute to a higher level of the euploid set of oocyte chromosomes and the development of a normal embryo after fertilization (Tanaka and Watanabe, Reference Tanaka and Watanabe2018). Whether GVT can save chromosomal abnormalities in age-related oocytes needs further study.

AUGMENT technology

Autologous germline mitochondrial energy transfer (AUGMENT) is the strategy launched by OvaScience in 2014 to transfer producing energy mitochondria from the autologous egg precursor cells into the oocytes. This action has been shown to enhance the quality of the egg and the fetus (Fakih et al., Reference Fakih, Shmoury, Szeptycki, dela Cruz, Lux, Verjee, Burgess, Cohn and Casper2015; Cozzolino et al., Reference Cozzolino, Marin and Sisti2019). The results from other researchers have indicated the lack of a positive effect on fertilization and development of euploid embryos for patients whose average age was 36.3 ± 3.6 years. Further studies on the effectiveness of this method on the oocytes of older women that are characterized using a pronounced decrease in energy reserves are required (Labarta et al., Reference Labarta, de Los Santos, Herraiz, Escribá, Marzal, Buigues and Pellicer2019).

Autologous mitochondrial injections are also performed with the use of cumulus and granulose cells that improve the fertilization rate, the quality of the embryos for 3 days, and the pregnancy rate (Tian et al., Reference Tian, Liu, Ye, Fu, Sheng, Wang, Wang, Heng and Liu2019; Tzeng et al., Reference Tzeng, Hsieh, Au, Yen, Chang and Cheng2004). However, the use of autologous mitochondrial injections is not recommended for mitochondrial mutations, which can increase with age.

Stem cells for germ cell production

Another alternative direction for the reproduction of advanced-age women is the reconstitution of gametogenesis in vitro. In the renewal of the ovarian reserve and the competence of germ cells, the production of mature gametes from germ cell progenitor stem cells, embryonic stem cells, the tail tip of fibroblasts, or even by reprogramming granulosa cells into oocytes is important (Hayashi et al., Reference Hayashi, Ogushi, Kurimoto, Shimamoto, Ohta and Saitou2012; Hikabe et al., Reference Hikabe, Hamazaki, Nagamatsu, Obata, Hirao, Hamada, Shimamoto, Imamura, Nakashima, Saitou and Hayashi2016; Tian et al., Reference Tian, Liu, Ye, Fu, Sheng, Wang, Wang, Heng and Liu2019). Successful in vitro reconstitution of primordial germ cells has recently had a significant effect on the field. The authors demonstrated the entire process of mammalian oogenesis in mice in vitro from primordial germ cells, in which the birth of fertile offspring was obtained from a cultured gonad (Morohaku et al., Reference Morohaku, Tanimoto, Sasaki, Kawahara-Miki, Kono, Hayashi, Hirao and Obata2016).

Skin-derived stem cells (SDSCs) constitute a heterogeneous population of stem cells generated in vitro from the dermis, which can be cultured as spherical aggregates of cells in suspension culture. Under certain in vitro or in vivo conditions, SDSCs show multipotency and can generate a variety of cell types (Ge et al., Reference Ge, Cheng, Dyce, De Felici and Shen2016). It has been shown that SDSCs are able to produce primordial germ cell-like cells in vitro, and even oocyte-like cells. Whether these germ cell-like cells can give rise to viable progeny remains, however, unknown.

Using platelet-rich plasma (PRP) therapy for fertility preservation of advanced-age women

Ovarian tissue rejuvenation due to the paracrine effect of PRP has become a fairly new and actively developing direction (Cakiroglu et al., Reference Cakiroglu, Saltik, Yuceturk, Karaosmanoglu, Kopuk, Scott, Tiras and Seli2020).

Many studies have documented that the use of PRP can reduce the signs of inflammation, postoperative blood loss, and infection and, in addition, lead to accelerated osteogenesis and the healing of wounds and soft tissues (Park et al., Reference Park, Yang and Chung2011). Many articles have reported that PRP therapy implementation can enhance healing and the anti-ageing process using angiogenesis regeneration due to the multiple growth factors and cytokines involved (Du and Lei, Reference Du and Lei2020).

PRP realizes its effects due to cytokines and growth factors that are contained in platelet granules, such as transforming growth factor-β, insulin-like growth factors 1 and 2 (IGF-1 and IGF-2), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), hepatocyte growth factor (HGF), basic fibroblast growth factor (bFGF), granulocyte colony-stimulating factor (G-CSF), and many others (Amable et al., Reference Amable, Carias, Teixeira, da Cruz Pacheco, Corrêa do Amaral, Granjeiro and Borojevic2013; Ramaswamy Reddy et al., Reference Ramaswamy Reddy, Reddy, Babu and Ashok2018).

The addition of Ca2+ to PRP leads to the release of platelet granule contents and the activation of processes induced by growth factors (Amable et al., Reference Amable, Carias, Teixeira, da Cruz Pacheco, Corrêa do Amaral, Granjeiro and Borojevic2013). PRP cryopreservation can activate platelet granules in addition to the advantage of prolonged shelf life (Kelly and Dumont, Reference Kelly and Dumont2019; Kleinveld et al., Reference Kleinveld, Juffermans, Noorman and Vincent2020).

The use of PRP therapy could be applied in the fight against infertility of women with a poor response, premature ovarian insufficiency, and late reproductive age, who do not want to carry out the oocyte donation programme, and make it possible to improve the hormonal background and activate folliculogenesis in the ovaries (Melo et al., Reference Melo, Navarro, Jones, Coward and Coleman2020; Sills et al., Reference Sills, Petersen, Rickers, Wood and Li2020).

Given the inverse relationship between ageing, growth hormone concentration, and IGF-1 (Fanciulli et al., Reference Fanciulli, Delitala and Delitala2009), the use of PRP reached in various cytokines and growth factors, including IGF-1, for injections into ovarian tissue led to an increase in cell proliferation and the follicle development.

It was shown that the injection of autologous PRP into the ovarian tissue of women with limited ovarian reserve or absence of menstruation for more than 1 year improved fertility in all patients aged 42 ± 4 years. Therefore, 5.3 ± 1.3 MII oocytes and at least one embryo suitable for freezing were received for each patient in the IVF cycle at 78 days after treatment (Sills et al., Reference Sills, Rickers, Li and Palermo2018). Similar results were obtained by other authors, who reported an improvement in hormonal status and pregnancy rate, including natural rates, after PRP therapy in women with low ovarian reserve (Petryk and Petryk, Reference Petryk and Petryk2020). Since 2019, several cases of childbirth after PRP therapy have been published, as well as the onset of natural pregnancy in women who had premature menopause (Farimani et al., Reference Farimani, Heshmati, Poorolajal and Bahmanzadeh2019; Pantos et al., Reference Pantos, Simopoulou, Pantou, Rapani, Tsioulou, Nitsos, Syrkos, Pappas, Koutsilieris and Sfakianoudis2019).

Except for injection into the ovarian tissue, PRP could be used to increase the effectiveness of oocyte in vitro maturation methods, which is relevant for patients with polycystic ovary syndrome, poor responders, and fertility preservation for women of different reproductive ages (Yurchuk, Reference Yurchuk2021). It has been shown that the addition of PRP into the maturation medium increased the quality of mature bovine oocytes (gametes with high mitochondrial potential) and led to an improvement in bovine embryo development (Moulavi et al., Reference Moulavi, Akram, Khorshid Sokhangouy and Hosseini2020; Ramos-Deus et al., Reference Ramos-Deus, Santos Nascimento, Vieira, Chaves, Albuquerque, Ferreira-Silva, Grázia, Santos Filho, Batista, Teixeira and Oliveira2020) Therefore, despite encouraging achievements of in vivo and in vitro PRP used for improving the fertility of patients with advanced maternal age, more extensive database evidence is requested.

The advantages and disadvantages of the main methods for improving oocyte function and fertility potential are listed in Table 1.

Table 1 The advantages and disadvantages of the methods for fertility preservation and improvement of the oocyte competence of advanced age patients.

Conclusion

The possibility of the realization of reproductive function in women in the late reproductive period is one of the most urgent problems of modern science. Assisted reproductive technologies have advanced in the field, not only for infertility in young women but also in older patients. Some approaches have been aimed at improving the reproductive function of women of late reproductive age by preserving fertility at an early age, namely by cryopreservation of oocytes or embryos. Physicians should inform all patients of reproductive age of their reduced fertility after the age of 35 and recommend not postponing pregnancy planning to late reproductive age or preserving fertility using cryopreservation techniques. Patients should be informed about the current possibilities of science to ensure the preservation of reproductive function through the use of cryotechnology and to allow them to make informed choices.

Other approaches have been aimed at improving the quality of oocytes and embryos obtained from women of late reproductive age. Among these technologies, the methods of mitochondrial replacement have been especially prominent as the main source of the ageing of female oocytes. These technologies are aimed at preserving the mother’s nuclear genotype to make possible the generation of, genetically, one’s own child in advanced reproductive age patients. Whilst these technologies are pushing the boundaries for manipulating female reproductive cells to achieve better outcomes in ART, the optimistic results of studies on gametogenesis reconstitution from somatic stem cells do not yet make it possible to implement them in clinical practice and require significant further research and validation. At the same time, the growing popularity of the use of PRP therapy to improve the reproductive hormonal background and activate folliculogenesis in women of older reproductive age requires further in-depth research and has good prospects for treatment.

Conflict of interests

The authors declare that there are no conflicts of interest.

References

Amable, P. R., Carias, R. B., Teixeira, M. V., da Cruz Pacheco, I., Corrêa do Amaral, R. J., Granjeiro, J. M. and Borojevic, R. (2013). Platelet-rich plasma preparation for regenerative medicine: Optimization and quantification of cytokines and growth factors. Stem Cell Research and Therapy, 4(3), 67. doi: 10.1186/scrt218 CrossRefGoogle ScholarPubMed
Asada, Y., Tokoro, M., Sonohara, M., Fukunaga, N., Hattori, Y. and Hashiba, Y. (2019). Long-term outcomes of freeze-all strategy: A retrospective analysis from a single ART center in Japan. Reproductive Medicine and Biology, 18(2), 173179. doi: 10.1002/rmb2.12264 CrossRefGoogle Scholar
American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. (2013). Assisted Reproductive Technology. National Summary Report. https://www.cdc.gov/art/pdf/2013-report/art_2013_national_summary_report.pdf Google Scholar
Barja, G. (2014). The mitochondrial free radical theory of ageing. Progress in Molecular Biology and Translational Science, 127, 127. doi: 10.1016/B978-0-12-394625-6.00001-5 CrossRefGoogle Scholar
Barritt, J. A., Brenner, C. A., Malter, H. E. and Cohen, J. (2001). Mitochondria in human offspring derived from ooplasmic transplantation. Human Reproduction, 16(3), 513516. doi: 10.1093/humrep/16.3.513 CrossRefGoogle ScholarPubMed
Borini, A., Levi Setti, P. E., Anserini, P., De Luca, R., De Santis, L., Porcu, E., La Sala, G. B., Ferraretti, A., Bartolotti, T., Coticchio, G. and Scaravelli, G. (2010). Multicenter observational study on slow-cooling oocyte cryopreservation: Clinical outcome. Fertility and Sterility, 94(5), 16621668. doi: 10.1016/j.fertnstert.2009.10.029 CrossRefGoogle ScholarPubMed
Bromfield, J. J., Coticchio, G., Hutt, K., Sciajno, R., Borini, A. and Albertini, D. F. (2009). Meiotic spindle dynamics in human oocytes following slow cooling cryopreservation. Human Reproduction, 24(9), 21142123. doi: 10.1093/humrep/dep182 CrossRefGoogle ScholarPubMed
Buderatska, N., Gontar, J., Ilyin, I., Lavrinenko, S., Petrushko, M. and Yurchuk, T. (2020). Does human oocyte cryopreservation affect equally on embryo chromosome aneuploidy? Cryobiology, 93, 3336. doi: 10.1016/j.cryobiol.2020.03.002 CrossRefGoogle ScholarPubMed
Buderatska, N. O and Petrushko, M. P. (2016). Oocytes as alternative to embryos in cryopreservation applied in assisted reproductive technologies. Problems of Cryobiology and Cryomedicine, 26(4), 375382. doi: 10.15407/cryo26.04.375 CrossRefGoogle Scholar
Cakiroglu, Y., Saltik, A., Yuceturk, A., Karaosmanoglu, O., Kopuk, S. Y., Scott, R. T., Tiras, B. and Seli, E. (2020). Effects of intraovarian injection of autologous platelet rich plasma on ovarian reserve and IVF outcome parameters in women with primary ovarian insufficiency. Aging, 12(11), 1021110222. doi: 10.18632/aging.103403 CrossRefGoogle ScholarPubMed
Capalbo, A., Rienzi, L., Cimadomo, D., Maggiulli, R., Elliott, T., Wright, G., Nagy, Z. P. and Ubaldi, F. M. (2014). Correlation between standard blastocyst morphology, euploidy and implantation: An observational study in two centers involving 956 screened blastocysts. Human Reproduction, 29(6), 11731181. doi: 10.1093/humrep/deu033 CrossRefGoogle ScholarPubMed
Chahal, H. S. and Drake, W. M. (2007). The endocrine system and ageing. Journal of Pathology, 211(2), 173180. doi: 10.1002/path.2110 CrossRefGoogle ScholarPubMed
Cil, A. P. and Seli, E. (2013). Current trends and progress in clinical applications of oocyte cryopreservation. Current Opinion in Obstetrics and Gynecology, 25(3), 247254. doi: 10.1097/GCO.0b013e32836091f4 CrossRefGoogle ScholarPubMed
Cimadomo, D., Fabozzi, G., Vaiarelli, A., Ubaldi, N., Ubaldi, F. M. and Rienzi, L. (2018). Impact of maternal age on oocyte and embryo competence. Frontiers in Endocrinology, 9, 327. doi: 10.3389/fendo.2018.00327 CrossRefGoogle ScholarPubMed
Cohen, J., Scott, R., Schimmel, T., Levron, J. and Willadsen, S. (1997). Birth of infant after transfer of anucleate donor oocyte cytoplasm into recipient eggs. Lancet, 350(9072), 186187. doi: 10.1016/S0140-6736(05)62353-7 CrossRefGoogle ScholarPubMed
Cordeiro, F. B., Montani, D. A., Pilau, E. J., Gozzo, F. C., Fraietta, R. and Turco, E. G. L. (2018). Ovarian environment aging: Follicular fluid lipidomic and related metabolic pathways. Journal of Assisted Reproduction and Genetics, 35(8), 13851393. doi: 10.1007/s10815-018-1259-5 CrossRefGoogle ScholarPubMed
Costa, C. M., Santana, F. M., Vilanova, S. M. and Parente, D. M. (2016). Analysis of diseases related to mitochondrial DNA: A literature review. Revista Saúde em Foco, 3, 107123.Google Scholar
Cozzolino, M., Marin, D. and Sisti, G. (2019). New Frontiers in IVF: mtDNA and autologous germline mitochondrial energy transfer. Reproductive Biology and Endocrinology: RB&E, 17(1), 55. doi: 10.1186/s12958-019-0501-z CrossRefGoogle Scholar
Craven, L., Tang, M. X., Gorman, G. S., De Sutter, P. and Heindryckx, B. (2017). Novel reproductive technologies to prevent mitochondrial disease. Human Reproduction Update, 23(5), 501519. doi: 10.1093/humupd/dmx018 CrossRefGoogle ScholarPubMed
Craven, L., Tuppen, H. A., Greggains, G. D., Harbottle, S. J., Murphy, J. L., Cree, L. M., Murdoch, A. P., Chinnery, P. F., Taylor, R. W., Lightowlers, R. N., Herbert, M. and Turnbull, D. M. (2010). Pronuclear transfer in human embryos to prevent transmission of mitochondrial DNA disease. Nature, 465(7294), 8285. doi: 10.1038/nature08958 CrossRefGoogle ScholarPubMed
Du, R. and Lei, T. (2020). Effects of autologous platelet-rich plasma injections on facial skin rejuvenation. Experimental and Therapeutic Medicine, 19(4), 30243030. doi: 10.3892/etm.2020.8531 Google ScholarPubMed
ESHRE Guideline Group on Female Fertility Preservation, Anderson, R. A., Amant, F., Braat, D., D’Angelo, A., Chuva de Sousa Lopes, S. M., Demeestere, I., Dwek, S., Frith, L., Lambertini, M., Maslin, C., Moura-Ramos, M., Nogueira, D., Rodriguez-Wallberg, K. and Vermeulen, N. (2020). ESHRE guideline: female fertility preservation. Human Reproduction Open, 2020(4), hoaa052. doi: 10.1093/hropen/hoaa052 Google ScholarPubMed
Fakih, M. H., Shmoury, M. E., Szeptycki, J., dela Cruz, D. B., Lux, C., Verjee, S., Burgess, C. M., Cohn, G. M. and Casper, R. F. (2015). The AUGMENTSM treatment: Physician reported outcomes of the initial global patient experience. Journal of Fertilization: In Vitro, IVF-Worldwide, Reproductive Medicine, Genetics and Stem Cell Biology, 3, 154.Google Scholar
Fanciulli, G., Delitala, A. and Delitala, G. (2009). Growth hormone, menopause and ageing: No definite evidence for ‘rejuvenation’ with growth hormone. Human Reproduction Update, 15(3), 341358. doi: 10.1093/humupd/dmp005 CrossRefGoogle ScholarPubMed
Farimani, M., Heshmati, S., Poorolajal, J. and Bahmanzadeh, M. (2019). A report on three live births in women with poor ovarian response following intra ovarian injection of platelet-rich plasma (PRP). Molecular Biology Reports, 46(2), 16111616. doi: 10.1007/s11033-019-04609-w CrossRefGoogle ScholarPubMed
Fragouli, E., Spath, K., Alfarawati, S., Kaper, F., Craig, A., Michel, C. E., Kokocinski, F., Cohen, J., Munne, S. and Wells, D. (2015). Altered levels of mitochondrial DNA are associated with female age, aneuploidy, and provide an independent measure of embryonic implantation potential. PLOS Genetics, 11(6), e1005241. doi: 10.1371/journal.pgen.1005241 CrossRefGoogle ScholarPubMed
Fragouli, E. and Wells, D. (2015). Mitochondrial DNA assessment to determine oocyte and embryo viability. Seminars in Reproductive Medicine, 33(6), 401409. doi: 10.1055/s-0035-1567821 Google ScholarPubMed
Franasiak, J. M., Forman, E. J., Hong, K. H., Werner, M. D., Upham, K. M., Treff, N. R. and Scott, R. T., Jr. (2014). The nature of aneuploidy with increasing age of the female partner: A review of 15,169 consecutive trophectoderm biopsies evaluated with comprehensive chromosomal screening. Fertility and Sterility, 101(3), 656663.e1. doi: 10.1016/j.fertnstert.2013.11.004 CrossRefGoogle Scholar
Ge, W., Cheng, S. F., Dyce, P. W., De Felici, M. and Shen, W. (2016). Skin-derived stem cells as a source of primordial germ cell- and oocyte-like cells. Cell Death and Disease, 7(11), e2471. doi: 10.1038/cddis.2016.366 CrossRefGoogle ScholarPubMed
Gharanfoli, S., Shahverdi, A., Dalman, A., Ghaznavi, P., Alipour, H. and Eftekhari-Yazdi, P. (2020). Effect of maternal age on hippo pathway related gene expressions and protein localization pattern in human embryos. Cell Journal, 22(Suppl 1), 7480. doi: 10.22074/cellj.2020.6860 Google ScholarPubMed
Hayashi, K., Ogushi, S., Kurimoto, K., Shimamoto, S., Ohta, H. and Saitou, M. (2012). Offspring from oocytes derived from in vitro primordial germ cell like cells in mice. Science (New York, NY), 338(6109), 971975. doi: 10.1126/science.1226889 CrossRefGoogle ScholarPubMed
Hikabe, O., Hamazaki, N., Nagamatsu, G., Obata, Y., Hirao, Y., Hamada, N., Shimamoto, S., Imamura, T., Nakashima, K., Saitou, M. and Hayashi, K. (2016). Reconstitution in vitro of the entire cycle of the mouse female germ line. Nature, 539(7628), 299303. doi: 10.1038/nature20104 CrossRefGoogle ScholarPubMed
Ishii, T. and Hibino, Y. (2018). Mitochondrial manipulation in fertility clinics: Regulation and responsibility. Reproductive Biomedicine and Society Online, 5, 93109. doi: 10.1016/j.rbms.2018.01.002 CrossRefGoogle ScholarPubMed
Keefe, D., Kumar, M. and Kalmbach, K. (2015). Oocyte competency is the key to embryo potential. Fertility and Sterility, 103(2), 317322. doi: 10.1016/j.fertnstert.2014.12.115 CrossRefGoogle ScholarPubMed
Keefe, D. L., Marquard, K. and Liu, L. (2006). The telomere theory of reproductive senescence in women. Current Opinion in Obstetrics and Gynecology, 18(3), 280285. doi: 10.1097/01.gco.0000193019.05686.49 CrossRefGoogle ScholarPubMed
Kelly, K. and Dumont, L. J. (2019). Frozen platelets. Transfusion and Apheresis Science, 58(1), 2329. doi: 10.1016/j.transci.2018.12.013 CrossRefGoogle ScholarPubMed
Kim, S., Lee, Y., Lee, S. and Kim, T. (2018a). Ovarian tissue cryopreservation and transplantation in patients with cancer. Obstetrics and Gynecology Science, 61(4), 431442. doi: 10.5468/ogs.2018.61.4.431 CrossRefGoogle ScholarPubMed
Kim, S. G., Kim, Y. Y., Park, J. Y., Kwak, S. J., Yoo, C. S., Park, I. H., Sun, H. G., Kim, J. W., Lee, K. H., Park, H. D. and Chi, H. J. (2018b). Early fragment removal on in vitro fertilization day 2 significantly improves the subsequent development and clinical outcomes of fragmented human embryos. Clinical and Experimental Reproductive Medicine, 45(3), 122128. doi: 10.5653/cerm.2018.45.3.122 CrossRefGoogle ScholarPubMed
Kleinveld, D. J. B., Juffermans, N. P. and Noorman, F. (2020). The use of frozen platelets for the treatment of bleeding. In Vincent, J. L. (Ed.), Annual Update in Intensive Care and Emergency Medicine, pp. 317329. Springer, Cham. doi: 10.1007/978-3-030-37323-8_26 Google Scholar
Kuleshova, L., Gianaroli, L., Magli, C., Ferraretti, A. and Trounson, A. (1999). Birth following vitrification of a small number of human oocytes: Case report. Human Reproduction, 14(12), 30773079. doi: 10.1093/humrep/14.12.3077 CrossRefGoogle ScholarPubMed
Kuliev, A., Cieslak, J. and Verlinsky, Y. (2005). Frequency and distribution of chromosome abnormalities in human oocytes. Cytogenetic and Genome Research, 111(3–4), 193198. doi: 10.1159/000086889 CrossRefGoogle ScholarPubMed
Labarta, E., de Los Santos, M. J., Herraiz, S., Escribá, M. J., Marzal, A., Buigues, A. and Pellicer, A. (2019). Autologous mitochondrial transfer as a complementary technique to intracytoplasmic sperm injection to improve embryo quality in patients undergoing in vitro fertilization-a randomized pilot study. Fertility and Sterility, 111(1), 8696. doi: 10.1016/j.fertnstert.2018.09.023 CrossRefGoogle ScholarPubMed
Levi-Setti, P. E., Patrizio, P. and Scaravelli, G. (2016). Evolution of human oocyte cryopreservation: Slow freezing versus vitrification. Current Opinion in Endocrinology, Diabetes, and Obesity, 23(6), 445450. doi: 10.1097/MED.0000000000000289 CrossRefGoogle ScholarPubMed
Liu, Y., Han, M., Li, X., Wang, H., Ma, M., Zhang, S., Guo, Y., Wang, S., Wang, Y., Duan, N., Xu, B., Yin, J. and Yao, Y. (2017). Age-related changes in the mitochondria of human mural granulosa cells. Human Reproduction, 32(12), 24652473. doi: 10.1093/humrep/dex309 CrossRefGoogle ScholarPubMed
May-Panloup, P., Boucret, L., Chao de la Barca, J. M., Desquiret-Dumas, V., Ferré-L’Hotellier, V., Morinière, C., Descamps, P., Procaccio, V. and Reynier, P. (2016). Ovarian ageing: The role of mitochondria in oocytes and follicles. Human Reproduction Update, 22(6), 725743. doi: 10.1093/humupd/dmw028 CrossRefGoogle ScholarPubMed
Melo, P., Navarro, C., Jones, C., Coward, K. and Coleman, L. (2020). The use of autologous platelet-rich plasma (PRP) versus no intervention in women with low ovarian reserve undergoing fertility treatment: A non-randomized interventional study. Journal of Assisted Reproduction and Genetics, 37(4), 855863. doi: 10.1007/s10815-020-01710-z CrossRefGoogle ScholarPubMed
Mobarak, H., Heidarpour, M., Tsai, P. J., Rezabakhsh, A., Rahbarghazi, R., Nouri, M. and Mahdipour, M. (2019). Autologous mitochondrial microinjection; a strategy to improve the oocyte quality and subsequent reproductive outcome during aging. Cell and Bioscience, 9, 95. doi: 10.1186/s13578-019-0360-5 CrossRefGoogle ScholarPubMed
Morohaku, K., Tanimoto, R., Sasaki, K., Kawahara-Miki, R., Kono, T., Hayashi, K., Hirao, Y. and Obata, Y. (2016). Complete in vitro generation of fertile oocytes from mouse primordial germ cells. Proceedings of the National Academy of Sciences of the United States of America, 113(32), 90219026. doi: 10.1073/pnas.1603817113 CrossRefGoogle ScholarPubMed
Moshkdanian, G., Nematollahi-mahani, S. N., Pouya, F. and Nematollahi-mahani, A. (2011). Antioxidants rescue stressed embryos at a rate comparable with co-culturing of embryos with human umbilical cord mesenchymal cells. Journal of Assisted Reproduction and Genetics, 28(4), 343349. doi: 10.1007/s10815-010-9529-x CrossRefGoogle Scholar
Moulavi, F., Akram, R. T., Khorshid Sokhangouy, S. and Hosseini, S. M. (2020) Platelet rich plasma efficiently substitutes the beneficial effects of serum during in vitro oocyte maturation and helps maintain the mitochondrial activity of maturing oocytes. Growth Factors, 38(3–4), 152166. doi: 10.1080/08977194.2021.1900168 CrossRefGoogle ScholarPubMed
Pai, H. D., Baid, R., Palshetkar, N. P., Pai, A., Pai, R. D. and Palshetkar, R. (2021). Oocyte cryopreservation – Current scenario and future perspectives: A narrative review. Journal of Human Reproductive Sciences, 14(4), 340349. doi: 10.4103/jhrs.jhrs_173_21 Google ScholarPubMed
Pantos, K., Simopoulou, M., Pantou, A., Rapani, A., Tsioulou, P., Nitsos, N., Syrkos, S., Pappas, A., Koutsilieris, M. and Sfakianoudis, K. (2019). A case series on natural conceptions resulting in ongoing pregnancies in menopausal and prematurely menopausal women following platelet-rich plasma treatment. Cell Transplantation, 28(9–10), 13331340. doi: 10.1177/0963689719859539 CrossRefGoogle ScholarPubMed
Park, H. B., Yang, J. H. and Chung, K. H. (2011). Characterization of the cytokine profile of platelet rich plasma (PRP) and PRP-induced cell proliferation and migration: Upregulation of matrix metalloproteinase-1 and -9 in HaCaT cells. Korean Journal of Hematology, 46(4), 265273. doi: 10.5045/kjh.2011.46.4.265 CrossRefGoogle ScholarPubMed
Parmegiani, L., Cognigni, G. E., Bernardi, S., Ciampaglia, W., Pocognoli, P. and Filicori, M. (2009). Birth of a baby conceived from frozen oocytes of a 40-year-old woman. Reproductive Biomedicine Online, 18(6), 795798. doi: 10.1016/s1472-6483(10)60028-4 CrossRefGoogle ScholarPubMed
Pellestor, F., Andréo, B., Arnal, F., Humeau, C. and Demaille, J. (2003). Maternal aging and chromosomal abnormalities: New data drawn from in vitro unfertilized human oocytes. Human Genetics, 112(2), 195203. doi: 10.1007/s00439-002-0852-x CrossRefGoogle ScholarPubMed
Petrushko, M., Yurchuk, T., Piniaiev, V. and Buderatska, N. (2019). Cryopreservation of incomplete compacted morulae and preliminary biopsy of excluded fragments. Zygote (Cambridge, England), 27(6), 386391. doi: 10.1017/S0967199419000455 CrossRefGoogle ScholarPubMed
Petrushko, M. P. (2003). [Cytogenetic analysis of unfertilized human oocytes]. TSitologiia i Genetika, 37(6), 6065.Google ScholarPubMed
Petrushko, M. P., Yurchuk, T. O., Buderatska, N. O. and Piniaiev, V. I. (2018). Oolemma invagination of fresh and cryopreserved human oocytes during in vitro fertilization by ICSI. Problems of Cryobiology and Cryomedicine, 28(3), 258265. doi: 10.15407/cryo28.03.258 CrossRefGoogle Scholar
Petryk, N. and Petryk, M. (2020). Ovarian rejuvenation through platelet-rich autologous plasma (PRP)-a chance to have a baby without donor eggs, improving the life quality of women suffering from early menopause without synthetic hormonal treatment. Reproductive Sciences, 27(11), 19751982. doi: 10.1007/s43032-020-00266-8 CrossRefGoogle ScholarPubMed
Ramaswamy Reddy, S. H., Reddy, R., Babu, N. C. and Ashok, G. N. (2018). Stem-cell therapy and platelet-rich plasma in regenerative medicines: A review on pros and cons of the technologies. Journal of Oral and Maxillofacial Pathology, 22(3), 367374. doi: 10.4103/jomfp.JOMFP_93_18 CrossRefGoogle ScholarPubMed
Ramos-Deus, P., Santos Nascimento, P., Vieira, J. I. T., Chaves, M. S., Albuquerque, K. A., Ferreira-Silva, J. C., Grázia, J. G. V., Santos Filho, A. S., Batista, A. M., Teixeira, V. W. and Oliveira, M. A. L. (2020). Application of platelet-rich plasma in the in vitro production of bovine embryos. Tropical Animal Health and Production, 52(6), 29312936. doi: 10.1007/s11250-020-02307-5 CrossRefGoogle ScholarPubMed
Rienzi, L., Cobo, A., Paffoni, A., Scarduelli, C., Capalbo, A., Vajta, G., Remohí, J., Ragni, G. and Ubaldi, F. M. (2012). Consistent and predictable delivery rates after oocyte vitrification: An observational longitudinal cohort multicentric study. Human Reproduction, 27(6), 16061612. doi: 10.1093/humrep/des088 CrossRefGoogle ScholarPubMed
Seifer, D. B., Baker, V. L. and Leader, B. (2011). Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States. Fertility and Sterility, 95(2), 747750. doi: 10.1016/j.fertnstert.2010.10.011 CrossRefGoogle ScholarPubMed
Sills, E. S., Petersen, J. L., Rickers, N. S., Wood, S. H. and Li, X. (2020). Regenerative effect of intraovarian injection of activated autologous platelet rich plasma: Serum anti-Müllerian hormone levels measured among poor prognosis in vitro fertilization patients. Int. J. Regen. Medicine, 1, 25.Google Scholar
Sills, E. S., Rickers, N. S., Li, X. and Palermo, G. D. (2018). First data on in vitro fertilization and blastocyst formation after intraovarian injection of calcium gluconate-activated autologous platelet rich plasma. Gynecological Endocrinology, 34(9), 756760. doi: 10.1080/09513590.2018.1445219 CrossRefGoogle ScholarPubMed
Simopoulou, M., Sfakianoudis, K., Bakas, P., Giannelou, P., Papapetrou, C., Kalampokas, T., Rapani, A., Chatzaki, E., Lambropoulou, M., Lourida, C., Deligeoroglou, E., Pantos, K. and Koutsilieris, M. (2018). Postponing pregnancy through oocyte cryopreservation for social reasons: Considerations regarding clinical practice and the socio-psychological and bioethical issues involved. Medicina (Kaunas, Lithuania), 54(5), 76. doi: 10.3390/medicina54050076 CrossRefGoogle ScholarPubMed
Tachibana, M., Sparman, M., Sritanaudomchai, H., Ma, H., Clepper, L., Woodward, J., Li, Y., Ramsey, C., Kolotushkina, O. and Mitalipov, S. (2009). Mitochondrial gene replacement in primate offspring and embryonic stem cells. Nature, 461(7262), 367372. doi: 10.1038/nature08368 CrossRefGoogle ScholarPubMed
Tanaka, A. and Watanabe, S. (2018). Can cytoplasmic donation rescue aged oocytes? Reproductive Medicine and Biology, 18(2), 128139. doi: 10.1002/rmb2.12252 CrossRefGoogle ScholarPubMed
Taylor, R. W. and Turnbull, D. M. (2005). Mitochondrial DNA mutations in human disease. Nature Reviews. Genetics, 6(5), 389402. doi: 10.1038/nrg1606 CrossRefGoogle ScholarPubMed
Tian, C., Liu, L., Ye, X., Fu, H., Sheng, X., Wang, L., Wang, H., Heng, D. and Liu, L. (2019). Functional oocytes derived from granulosa cells. Cell Reports, 29(13), 42564267.e9. doi: 10.1016/j.celrep.2019.11.080 CrossRefGoogle ScholarPubMed
Tzeng, C. R., Hsieh, R. H., Au, H. K., Yen, Y. H., Chang, S. J. and Cheng, Y. F. (2004). Mitochondria transfer (MIT) into oocyte from autologous cumulus granulosa cells (cGCs). Fertility and Sterility, 82, Suppl. 53. doi: 10.1016/j.fertnstert.2004.07.136 CrossRefGoogle Scholar
Valeri, C., Pappalardo, S., De Felici, M. and Manna, C. (2011). Correlation of oocyte morphometry parameters with woman’s age. Journal of Assisted Reproduction and Genetics, 28(6), 545552. doi: 10.1007/s10815-011-9555-3 CrossRefGoogle ScholarPubMed
Wang, T., Sha, H., Ji, D., Zhang, H. L., Chen, D., Cao, Y. and Zhu, J. (2014). Polar body genome transfer for preventing the transmission of inherited mitochondrial diseases. Cell, 157(7), 15911604. doi: 10.1016/j.cell.2014.04.042 CrossRefGoogle ScholarPubMed
World Health Organization. (2006). Reproductive health indicators: guidelines for their generation, interpretation and analysis for global monitoring. World Health Organization, 63 pp.Google Scholar
World Health Organization. (2021). WHO laboratory manual for the examination and processing of human semen. 6th edition. World Health Organization, 276 pp.Google Scholar
Wu, J., Zhang, L. and Wang, X. (2000). Maturation and apoptosis of human oocytes in vitro are age-related. Fertility and Sterility, 74(6), 11371141. doi: 10.1016/s0015-0282(00)01597-1 CrossRefGoogle ScholarPubMed
Yoon, H. G., Yoon, S. H., Son, W. Y., Kim, J. G., Im, K. S. and Lim, J. H. (2001). Alternative embryo transfer on day 3 or day 5 for reducing the risk of multiple gestations. Journal of Assisted Reproduction and Genetics, 18(5), 262267. doi: 10.1023/a:1016651016502 CrossRefGoogle ScholarPubMed
Yurchuk, T. (2021). Cryopreservation of immature oocytes at germinal vesicle stage. when gamete maturation performance seems to be most appropriate? Problems of Cryobiology and Cryomedicine, 31(2), 161167. doi: 10.15407/cryo31.02.161 CrossRefGoogle Scholar
Zhang, J., Liu, H., Luo, S., Chavez-Badiola, A., Liu, Z., Yang, M., Munne, S., Konstantinidis, M., Wells, D. and Huang, T. (2016a). First live birth using human oocytes reconstituted by spindle nuclear transfer for mitochondrial DNA mutation causing Leigh syndrome. Fertility and Sterility, 106(3), e375e376. doi: 10.1016/j.fertnstert.2016.08.004 CrossRefGoogle Scholar
Zhang, J., Wang, C. W., Krey, L., Liu, H., Meng, L., Blaszczyk, A., Adler, A. and Grifo, J. (1999). In vitro maturation of human preovulatory oocytes reconstructed by germinal vesicle transfer. Fertility and Sterility, 71(4), 726731. doi: 10.1016/s0015-0282(98)00549-4 CrossRefGoogle ScholarPubMed
Zhang, J., Zhuang, G., Zeng, Y., Grifo, J., Acosta, C., Shu, Y. and Liu, H. (2016b). Pregnancy derived from human zygote pronuclear transfer in a patient who had arrested embryos after IVF. Reproductive Biomedicine Online, 33(4), 529533. doi: 10.1016/j.rbmo.2016.07.008 CrossRefGoogle Scholar
Zhang, J. J., Choo, S. and Yang, M. (2015). Autologous oocyte cryopreservation in women aged 40 and older using minimal stimulation IVF. Reproductive Biology and Endocrinology: RB&E, 13, 112. doi: 10.1186/s12958-015-0110-4 CrossRefGoogle ScholarPubMed
Zhang, M., Lu, Y., Chen, Y., Zhang, Y. and Xiong, B. (2020). Insufficiency of melatonin in follicular fluid is a reversible cause for advanced maternal age-related aneuploidy in oocytes. Redox Biology, 28, 101327. doi: 10.1016/j.redox.2019.101327 CrossRefGoogle ScholarPubMed
Zou, W., Slone, J., Cao, Y. and Huang, T. (2020). Mitochondria and their role in human reproduction. DNA and Cell Biology, 39(8), 13701378. doi: 10.1089/dna.2019.4807 CrossRefGoogle ScholarPubMed
Figure 0

Table 1 The advantages and disadvantages of the methods for fertility preservation and improvement of the oocyte competence of advanced age patients.